2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Molecular Testing, Pathology, Treatment Considerations, Supportive Care, Therapy Sequence, Biological Therapies, Transfusion, Immunotherapy, Non-Biological Therapies, Anticoagulant Drugs, Women’s Health, Adverse Events, Clinical Practice (Health Services and Quality), Clinical Guidelines, Quality of Care, Systems-Based Hematology, Value, Diseases, Bleeding and Clotting, Bleeding Disorders, Hemophilia, Thromboembolism, Thrombotic Disorders, Bone Marrow Failure Syndromes, Acquired Marrow Failure Syndromes , Inherited Marrow Failure Syndromes, Aplastic Anemia, Genetic Disorders, Immunology, Autoimmune Hemolytic Anemia, Neutropenia, Infectious Diseases, Viral, Bacterial, Fungal, Myeloid Malignancies, Chronic Myeloid Malignancies, Metabolic Disorders, Iron Deficiency, Research, MPN, Clinical Research, Epidemiology, Health Outcomes Research, Health Disparities Research, Patient-Reported Outcomes, Real-World Evidence, Study Population, Human, Adult, Pediatric, Pregnant, Young Adult
PAPER

6216 Impact of GLP-1 receptor agonists on venous thromboembolic risk in nondiabetic patients with obesity: A real-world retrospective multi-center analysis

Richard Wu, MD, Alec Seidman Sorsby, MD2
1 Boston Medical Center, Boston, United States
2 Boston Medical Center, Boston, United States

Background: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are widely prescribed weight and diabetic management medications that have rapidly grown in popularity due to their efficacy and expanding evidence for multi-target mechanisms of action. There have been limited studies evaluating the efficacy of GLP-1RAs on the incidence of venous thromboembolisms (VTEs) in patients with diabetes, and even less data evaluating the same in patients without diabetes. These patients who are prescribed GLP-1RAs solely for weight loss do not have the additional prothrombotic consequences of diabetes, and may have unique factors influencing their VTE risk that may be independent of any fluctuations in weight. Clarifying this difference is important to better understanding the impact of this class of medications on VTE incidence and what role they may play in patient risk stratification.

Methods: We conducted a real-world retrospective cohort study utilizing the TriNetX Research Network database, a multicenter federated electronic health record platform including de-identified data from 114 healthcare organizations, evaluating the effect of GLP-1RAs on VTE incidence. Adults aged 18 years or older with a BMI ≥ 30 kg/m2 with no prior diagnosis of diabetes mellitus, no A1c level ≥ 6.5%, and no past history of acute or chronic deep vein thromboses, pulmonary emboli, or long-term use of anticoagulants and antiplatelets were eligible for inclusion. The use of a GLP-1RA was evaluated against an active comparator of phentermine or orlistat use, and prescriptions of these medications must have continued for a minimum of one year to qualify patients for analysis. Baseline characteristics were ascertained from the 90 days prior to index, defined as the 365th day of an active prescription of a GLP-1RA or phentermine/orlistat . Propensity matching was conducted using 1:1 greedy nearest-neighbor matching based on demographic and laboratory data, body mass index (BMI) at the time of index, and VTE risk-modifying factors including medical and cancer history, estrogen use, genetic factors, and tobacco use. The primary outcome of interest was the incidence of new VTE at 5 years. Secondary outcomes included the incidence of pulmonary embolism, and the overall risk of mortality.

Results: 64,601 patients in the GLP-1RA exposure cohort and 27,831 in the phentermine/orlistat cohort met criteria for inclusion. After propensity matching, 27,297 patients remained in each cohort. GLP-1RAs were not found to be associated with a statistically significant difference in incident VTE rates (HR 1.71, 95% CI 0.83 - 3.55; p = 0.1427), nor in the incidence of pulmonary emboli (HR 1.67, 95% CI 0.76 - 3.68; p = 0.2006) or mortality (HR 1.06, 95% CI 0.78 - 1.45; p = 0.7031) at five years post-index when compared to patients prescribed phentermine or orlistat.

Conclusion: This real-world multi-center retrospective study suggests a lack of benefit from GLP-1RAs on reducing incident VTE rates or mortality when propensity matched for BMI and VTE risk factors against an active comparator weight-loss medication. Previous studies on patients using GLP-1RAs for diabetes have suggested a reduction in VTE rates in patients on this medication class. This disparate result suggests the need to further delineate whether this is a diabetic-specific effect or if confounding factors influenced results in some way. Our data benefits from the large size of the included patient population and strong propensity matching, but faces risks of residual confounding and dependence on electronic health record coding due to the study design. Further prospective studies are needed to better understand the effect of GLP-1RAs on VTE risk to clarify its effect on risk calculations.

Alec Seidman Sorsby, MD: No relevant conflicts of interest to declare.